4/18
10:23 am
argx
argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $521.00 price target on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $521.00 price target on the stock.
4/18
08:04 am
argx
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.
4/16
01:00 am
argx
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
Low
Report
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
3/29
04:58 am
argx
Here's Why argenx SE (ARGX) Pulled Back 23% in Q4 [Yahoo! Finance]
Low
Report
Here's Why argenx SE (ARGX) Pulled Back 23% in Q4 [Yahoo! Finance]
3/27
10:56 am
argx
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.
3/27
02:00 am
argx
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
Low
Report
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
3/26
04:00 pm
argx
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
Low
Report
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
3/26
08:12 am
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Scotiabank from $402.00 to $408.00. They now have a "sector perform" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Scotiabank from $402.00 to $408.00. They now have a "sector perform" rating on the stock.
3/26
02:00 am
argx
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
Low
Report
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
3/22
01:46 pm
argx
argenx SE (NASDAQ: ARGX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $471.00 price target on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $471.00 price target on the stock.
3/19
07:28 am
argx
Reasons to Invest in argenx (ARGX) [Yahoo! Finance]
Low
Report
Reasons to Invest in argenx (ARGX) [Yahoo! Finance]
3/7
04:01 pm
argx
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
Low
Report
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
3/7
07:36 am
argx
Should You be Confident in Your Investment in argenx SE (ARGX)? [Yahoo! Finance]
Low
Report
Should You be Confident in Your Investment in argenx SE (ARGX)? [Yahoo! Finance]
3/5
08:14 am
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Truist Financial Co. from $370.00 to $440.00. They now have a "buy" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Truist Financial Co. from $370.00 to $440.00. They now have a "buy" rating on the stock.
3/1
12:38 pm
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Scotiabank from $346.00 to $402.00. They now have a "sector perform" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Scotiabank from $346.00 to $402.00. They now have a "sector perform" rating on the stock.
3/1
11:48 am
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at JMP Securities from $462.00 to $471.00. They now have a "market outperform" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at JMP Securities from $462.00 to $471.00. They now have a "market outperform" rating on the stock.
3/1
08:14 am
argx
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.
Medium
Report
argenx SE (NASDAQ: ARGX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $451.00 price target on the stock.
3/1
08:13 am
argx
argenx SE (NASDAQ: ARGX) had its price target lowered by analysts at Robert W. Baird from $505.00 to $490.00. They now have an "outperform" rating on the stock.
Medium
Report
argenx SE (NASDAQ: ARGX) had its price target lowered by analysts at Robert W. Baird from $505.00 to $490.00. They now have an "outperform" rating on the stock.
2/29
01:00 am
argx
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
Medium
Report
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
2/26
01:00 am
argx
argenx to Present at Upcoming Investor Conferences
Low
Report
argenx to Present at Upcoming Investor Conferences
2/22
01:00 am
argx
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
Low
Report
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
2/20
12:10 pm
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Wells Fargo & Company from $472.00 to $478.00. They now have an "overweight" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Wells Fargo & Company from $472.00 to $478.00. They now have an "overweight" rating on the stock.
2/20
01:00 am
argx
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Low
Report
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
2/15
07:17 am
argx
argenx SE (NASDAQ: ARGX) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
1/26
02:53 pm
argx
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Piper Sandler from $518.00 to $522.00. They now have an "overweight" rating on the stock.
Low
Report
argenx SE (NASDAQ: ARGX) had its price target raised by analysts at Piper Sandler from $518.00 to $522.00. They now have an "overweight" rating on the stock.